Rx for FDA Inaction: Competition
The FDA won't reform itself because it is a monopoly, argues Peter Barton Hutt. His solution: competition: if either the European Medicines Evaluation Agency or the UK's Medicines Control Agency approves a drug, the FDA would have 90 days to veto a sponsor's application for approval--any veto having to be accompanied by a specific clinical rationale.
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.